BioMelbourne Network Progressing BioIndustry

3rd September - 'In Conversation with Thomas Lönngren: An Intimate EU-Global Regulatory Workshop'
Facilitated by Ned and Sarah Kilpatrick of Greengage Regulatory Consultancy. More

BioMelbourne Network

The BioMelbourne Network is a membership based, industry forum representing business leaders in biotechnology, medical technology and innovation industries in Victoria. The power of our network resides with our members, who are some of the largest life sciences companies in Australia. Our mission is to support, connect and enable growth of our sector, through networking and professional development events that provide access to industry intelligence and promote peer-to-peer knowledge exchange.

STA: License Agreement with PharmaMar to Market, Distribute Oncology Drug APLIDIN® (plitidepsin) in AU and NZ

21 August 2015.  Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN® (plitidepsin) in Australia and New Zealand. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties... read more…

Gordagen Receives $1.1m R&D Tax Incentive to Progress Clinical Development Program

18 August 2015.  Gordagen Pharmaceuticals, an Australian private company developing and commercialising tocotrienol-based biopharmaceuticals and nutraceuticals, is pleased to announce it has received a Research and Development Tax Incentive refund of AUD$1.1 million for the 2014/2015 financial year. Gordagen intends to apply these funds to continue progressing its ICH-GCP clinical development p... read more…

Invion Completes Clinical Trial of INV103 (ALA-CPN10) in Lupus Patients

17 August 2015.  Australian drug development  company  Invion  Limited  (ASX:  IVX)  has  completed  its  Phase  II  clinical  trial  entitled “Double-blinded,   randomised,   placebo-controlled   study   to   investigate   the   safety,   tolerability, pharmacokinetics, and biochemical activity of intravenous Cpn10 administration in subjects with SLE (NCT01838694)”.The Company’s decision to co... read more…

Science is Golden podcast episode 1: Dora Lush, the Australian scientist and war hero

17 August 2015.  Australian medical researcher Dora Lush died in the most heroic of circumstances, but you've probably never heard of her.Neither had I, and I write about Australian scientists for a living.While conducting experiments on the deadly scrub typhus infection in 1943 the young researcher pricked her finger with an infected needle.Within a week she had symptoms of the disease - fever... read more…

Gordagen Engages Ascendiant Capital Markets for Investment Banking Services

13 August 2015.  Gordagen Pharmaceuticals, a private biopharmaceutical and nutraceutical company developing and commercialising pharmaceuticals and nutraceuticals based on tocotrienols, today announced its engagement with Ascendiant Capital Markets LLC. to serve as the Company's U.S Investment Banker and corporate financial advisor.Dr. Glenn Tong, CEO and Managing Director of Gordagen Pharmaceu... read more…

IDT Australia Partners with ANI Pharmaceuticals to Commercialise IDT’s US Generic Drug Products

12 August 2015.  ANI Pharmaceuticals Inc. to become IDT’s US partner in the distribution of IDT’s generic drug products Targeting launch of the products in calendar 2016 IDT Australia Limited (IDT.AX) has completed a major commercial milestone with an agreement with US-based ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) to market and distribute in the US up to eighteen of IDT’s recently acqu... read more…

"When cities and regions flourish, our country flourishes" - Prime Minister Tony Abbott

6 August 2015. I couldn't agree more with this statement made by the PM this morning, when he announced a new Industry Growth Centre in Advanced Manufacturing for Deakin University. "Geelong will be the heart of advanced manufacturing in Australia" said Ian MacFarlane Minister for Industry and Science, who spoke of the amazing future Australia has in high-tech high-value manufacturing. Th... read more…

“Melbourne is the city that anchors Australia’s Innovation System”

3 August 2015.  Today Dr Krystal Evans CEO of the BioMelbourne Network gave evidence to the Senate Economics References Committee regarding the Senate Inquiry into Australia’s Innovation System. In her testimony she emphasised the need for a long-term vision for our nation’s future and consistent bi-partisan commitment to innovation. Dr Evans said that consultation with BioMelbourne Network mem... read more…

New Minister for Small Buiness, Innovation and Trade

31 July 2015.  The BioMelbourne Network welcomes the appointment of Victorian Upper House Labor MP Philip Dalidakis as the new Minister for Small Business, Innovation and Trade. We look forward to working the Minister in supporting innovative businesses and entrepreneurship in the biotechnology and medical technology sector. Melbourne is the city that anchors Australia’s innovation ecosystem. ... read more…

Gordagen Appoints Gregory Macosko to Board of Directors

29 July 2015.  Gordagen Pharmaceuticals, a private biopharmaceutical and nutraceutical company developing tocotrienols, today announced the appointment of Gregory Macosko to its board of directors, effective August 1, 2015.  With this addition, its Board now consists of 5 directors of which 3 directors are non-executive and independent.Mr. Fred Nadjarian, the Chairman of Gordagen Pharmaceutical... read more…

Invion and Hovione Sign Joint Development and Licensing Agreement for Inhaled Zafirlukast

27 July 2015.  Australian drug development company Invion Limited (ASX: IVX)  has secured a commitment from Hovione Scientia Limited, an international pharmaceutical company expert in inhalation development and manufacturing, to progress development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.Invion and Hovione will collaborate to develop the proprietary novel techno... read more…

BioMelbourne Network - New Phone Number

We have a new phone number, please update your records and remove the old number.  BioMelbourne Network's new number is +61 (0)3 9667 8181 Nicole Pitcher Office Manager BioMelbourne Network Milton House, Level 2, 25 Flinders Lane Melbourne  Australia  3000 tel: +61 (0)3 9667 8181 mobile: +61 (0)409 182 900 email: npitcher@biomelbourne.org internet: www.biomelbourne.org   read more…

ARC Imaging Centre Work on Nanoparticles Published Today in Science

17 July 2015.  ARC Imaging Centre Work on Nanoparticles Published Today in Science. We are delighted to announce that our ARC Imaging Centre Associate Investigator Hans Elmlund's work on the structure of platinum nanoparticles has been published in Science today. Hans, a structural biologist at Monash University, worked with international colleagues including scientists at Berkeley, Princeton a... read more…

Gordagen Appoints Dr. Rocco Iannello as Director of Business Development

16 July 2015.  Gordagen Appoints Dr. Rocco Iannello as Director of Business Development. Gordagen Pharmaceuticals, a private biopharmaceutical and nutraceutical company developing tocotrienols, today announced the appointment of Dr. Rocco Iannello as Director of Business Development.Dr. Iannello will be responsible for Gordagen’s business development, including major international licensing a... read more…

MMV wins Tim Berners-Lee’s Open Data Innovation Award

14 July 2015.  Nominated by UK DFID, MMV chosen from a shortlist of 17 open data pioneers.MMV has won the Open Data Innovation Award, one of Five Open Data Awards presented by Tim Berners-Lee’s Open Data Institute (ODI) and hosted at Bloomberg London. The awards presented On Thursday, 9 July 2015, were in recognition of innovation and excellence in open data. MMV was one of 17 organizations sho... read more…

Global Biotech Industry Continues to Sizzle as Market Capitalization Surpasses US$1 Trillion

8 July 2015.  The global biotechnology industry reached new heights in 2014, setting records on virtually every major financial metric, including revenues, profitability and capital raised. These positive performance indicators, combined with several high-profile product successes and a strong year for new drug approvals, drove the industry’s total market capitalization above the US$1t threshol... read more…

BioMelbourne Network Announces Incoming Chair

8 July 2015.The BioMelbourne Network is pleased to announce that Mr Andrew Carter has been elected by the Board to succeed Mr Andrew Macdonald as Chair, effective from the 1st of July, 2015. Mr Andrew Macdonald has completed a distinguished period of service as Chair of the Network, following his appointment to the role in 2010. Andrew has provided strong leadership in overseeing the growth and... read more…

Nexvet and Zenoaq Enter Research and Development Collaboration

7 July 2015.  DUBLIN, Ireland, July 7, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the signing of a research and development agreement with leading Japanese animal health company Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.) to develop a number of therapeutic biologics for companion animals. The biologics will target undisclosed pro... read more…

Circadian Commences Wet AMD OPT-302 Clinical Trial

1 July 2015.  Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) has commenced its Phase 1 study of OPT-302 in patients with wet age-related macular degeneration (wet AMD) following receipt of Institutional Review Board (IRB) approval and initiation of the five clinical trial sites in the US. The trial is under an investigational new drug (IND) authorisation received from the US Food and Dru... read more…

Invion Completes Dosing in Key Phase II Clinical Trial of Oral INV102 (NADOLOL) in Smoking Cessation

29 June 2015.  Invion Limited (ASX: IVX), an Australian drug development company, is pleased to announce that it   has completed dosing in INVSC001: “Efficacy and safety of beta-adrenoceptor inverse agonist, nadolol, in smoking cessation of patients with pre-existing COPD”.This double-blind, randomized, placebo-controlled Phase IIB clinical trial, is being performed in the United States under a... read more…